Literature DB >> 17118986

Oxidant generation by single infected monocytes after short-term fluorescence labeling of a protozoan parasite.

Haeok K Chang1, Colin Thalhofer, Breck A Duerkop, Joanna S Mehling, Shilpi Verma, Kenneth J Gollob, Roque Almeida, Mary E Wilson.   

Abstract

Leishmania spp. are intracellular protozoa residing in mononuclear phagocytes. Leishmania organisms are susceptible to microbicidal responses generated in response to phagocytosis. Assuming that both phagocyte and parasite populations are heterogeneous, it is advantageous to examine the response of individual cells phagocytosing living parasites. Because Leishmania spp. lose virulence during the raising of transfectants, we developed a method to label live Leishmania chagasi short-term with fluorescent dyes. Up to six parasite divisions were detected by flow cytometry after labeling with carboxyfluorescein diacetate succinimidyl ester (CFSE), dioctadecyl-tetramethylindo carbocyanine perchlorate, or chloromethyl tetramethylrhodamine. Labeled parasites entered mononuclear phagocytes as determined by confocal and time-lapse microscopy. Dihydroethidium (DHE) was used to detect macrophage-derived oxidants generated during phagocytosis. Presumably Leishmania organisms are opsonized with host serum/tissue components such as complement prior to phagocytosis. Therefore, we investigated the effects of opsonization and found that this increased the efficiency of CFSE-labeled parasite entry into monocytes (84.6% +/- 8.8% versus 20.2% +/- 3.8% monocytes infected; P < 0.001). Opsonization also increased the percentage of phagocytes undergoing a respiratory burst (66.0% +/- 6.3% versus 41.0% +/- 8.3% of monocytes containing CFSE-labeled parasites; P < 0.001) and the magnitude of oxidant generation by each infected monocyte. Inhibitor data indicated that DHE was oxidized by products of the NADPH oxidase. These data suggest that opsonized serum components such as complement lead to more efficient entry of Leishmania into their target cells but at the same time activate the phagocyte oxidase to generate microbicidal products in infected cells. The parasite must balance these positive and negative survival effects in order to initiate a viable infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118986      PMCID: PMC1828521          DOI: 10.1128/IAI.00914-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo.

Authors:  Jianping Yang; Stephanie P Huck; Rebecca S McHugh; Ian F Hermans; Franca Ronchese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

2.  Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages.

Authors:  Nilda E Rodríguez; Upasna Gaur; Mary E Wilson
Journal:  Cell Microbiol       Date:  2006-07       Impact factor: 3.715

Review 3.  Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view.

Authors:  Martin Olivier; David J Gregory; Geneviève Forget
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani.

Authors:  R D Pearson; J L Harcus; P H Symes; R Romito; G R Donowitz
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

5.  Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity.

Authors:  Paulo E A Souza; Manoel O C Rocha; Etel Rocha-Vieira; Cristiane A S Menezes; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

6.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

7.  A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages.

Authors:  J Y Channon; M B Roberts; J M Blackwell
Journal:  Immunology       Date:  1984-10       Impact factor: 7.397

8.  Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes.

Authors:  S D Wright; S C Silverstein
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

9.  Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.

Authors:  J M Blackwell; R A Ezekowitz; M B Roberts; J Y Channon; R B Sim; S Gordon
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  18 in total

1.  Human immune response to salivary proteins of wild-caught Phlebotomus papatasi.

Authors:  Rami M Mukbel; Rehab H Khasharmeh; Nawal S Hijjawi; Mohammed S Khalifeh; Ma'mon M Hatmal; Mary Ann McDowell
Journal:  Parasitol Res       Date:  2016-05-10       Impact factor: 2.289

2.  Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species.

Authors:  Fernanda O Novais; Ba T Nguyen; Daniel P Beiting; Lucas P Carvalho; Nelson D Glennie; Sara Passos; Edgar M Carvalho; Phillip Scott
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

3.  The effects of macrophage source on the mechanism of phagocytosis and intracellular survival of Leishmania.

Authors:  Chia-Hung Christine Hsiao; Norikiyo Ueno; Jian Q Shao; Kristin R Schroeder; Kenneth C Moore; John E Donelson; Mary E Wilson
Journal:  Microbes Infect       Date:  2011-06-30       Impact factor: 2.700

4.  The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis.

Authors:  Smriti Sharma; Shweta Srivastva; Richard E Davis; Siddharth Sankar Singh; Rajiv Kumar; Susanne Nylén; Mary E Wilson; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

5.  Leishmania infantum chagasi: a genome-based approach to identification of excreted/secreted proteins.

Authors:  Sruti DebRoy; Alexandra B Keenan; Norikiyo Ueno; Selma M B Jeronimo; John E Donelson; Mary E Wilson
Journal:  Exp Parasitol       Date:  2010-06-11       Impact factor: 2.011

6.  Kinetic analysis of ex vivo human blood infection by Leishmania.

Authors:  Inmaculada Moreno; Mercedes Domínguez; Darío Cabañes; Carmen Aizpurua; Alfredo Toraño
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

7.  Differences in human macrophage receptor usage, lysosomal fusion kinetics and survival between logarithmic and metacyclic Leishmania infantum chagasi promastigotes.

Authors:  Norikiyo Ueno; Carol L Bratt; Nilda E Rodriguez; Mary E Wilson
Journal:  Cell Microbiol       Date:  2009-08-20       Impact factor: 3.715

8.  Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts.

Authors:  Upasna Gaur; Melissa Showalter; Suzanne Hickerson; Rahul Dalvi; Salvatore J Turco; Mary E Wilson; Stephen M Beverley
Journal:  Exp Parasitol       Date:  2009-03-27       Impact factor: 2.011

9.  Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion.

Authors:  Chaoqun Yao; Upasna Gaur Dixit; Jason H Barker; Lynn M Teesch; Laurie Love-Homan; John E Donelson; Mary E Wilson
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

10.  Infection and Activation of Human Neutrophils with Fluorescent Leishmania infantum.

Authors:  R E Davis; C J Thalhofer; M E Wilson
Journal:  J Immunol Tech Infect Dis       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.